Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Enasidenib after Salvage Therapy in IDH2-Mutated AML
NCT03881735Phase 2Withdrawn
- Sponsor
- Roswell Park Comprehensive Cancer Center
- Start
- Dec 2019
- Primary completion
- Nov 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of enasidenib in acute myeloid leukemia (AML), sponsored by Roswell Park Comprehensive Cancer Center. Planned start Dec 2019; status: withdrawn.
02
Drugs
enasidenib
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT03881735.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03881735.